Erste Group Bank Brokers Lower Earnings Estimates for Amgen

Key Points

• Erste Group Bank lowered Amgen’s FY2027 EPS estimate to $23.50 from $23.58 and maintained a “Hold” rating. The revised estimate remains above the current full-year consensus of $22.78.
• Amgen reported a strong latest quarter, with EPS of $6.29 beating the $5.62 consensus and revenue of $10.05 billion rising 9.5% year over year. Management provided FY2026 EPS guidance of $22.30–$23.50.
• Analyst sentiment remains mixed: Amgen has a consensus “Hold” rating and an average price target of $370.07, despite several firms raising their targets. The company also declared a quarterly dividend of $2.52 per share, implying a 2.5% yield.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Stock analysts at Erste Group Bank reduced their FY2027 EPS estimates for shares of Amgen in a research report issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the medical research company will post earnings of $23.50 per share for the year, down from their previous estimate of $23.58. Erste Group Bank currently has a "Hold" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $22.78 per share.

A number of other analysts have also recently commented on the company. Weiss Ratings raised Amgen from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday. Oppenheimer boosted their price objective on shares of Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. Mizuho upped their target price on shares of Amgen from $295.00 to $303.00 and gave the company a "neutral" rating in a research note on Tuesday, June 16th. Morgan Stanley increased their target price on shares of Amgen from $333.00 to $351.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Finally, Citigroup raised their price target on Amgen from $345.00 to $405.00 and gave the stock a "neutral" rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $370.07.

Amgen Stock Performance

NASDAQ AMGN opened at $410.95 on Monday. Amgen has a 12 month low of $269.77 and a 12 month high of $418.40. The stock has a 50-day simple moving average of $362.77 and a 200 day simple moving average of $356.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The company has a market capitalization of $222.17 billion, a PE ratio of 25.54, a P/E/G ratio of 3.82 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the company earned $6.02 EPS. The firm's revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

Institutional Trading of Amgen

A number of institutional investors have recently made changes to their positions in AMGN. Roman Butler Fullerton & Co. increased its position in Amgen by 1.4% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company's stock valued at $705,000 after buying an additional 27 shares in the last quarter. High Note Wealth LLC boosted its holdings in Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock worth $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. grew its stake in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company's stock worth $1,351,000 after acquiring an additional 28 shares during the last quarter. Verus Capital Partners LLC increased its holdings in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company's stock valued at $403,000 after acquiring an additional 28 shares in the last quarter. Finally, Destination Wealth Management raised its position in shares of Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company's stock valued at $456,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company's stock.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source